.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,683,867

« Back to Dashboard

Details for Patent: 5,683,867

Title: Systematic evolution of ligands by exponential enrichment: blended SELEX
Abstract:A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl (SEQ ID NO:2) ketone. This elastase blended nucleic acid ligand inhibits the biological activity of elastase.
Inventor(s): Biesecker; Greg (Boulder, CO), Jayasena; Sumedha D. (Boulder, CO), Gold; Larry (Boulder, CO), Smith; Drew (Boulder, CO), Kirschenheuter; Gary P. (Arvada, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Apr 28, 1994
Application Number:08/234,997
Claims:1. A method for identifying blended nucleic acid ligands of a target compound from a blended candidate mixture comprised of blended nucleic acids wherein each blended nucleic acid comprises a nucleic acid sequence region and a functional unit, wherein said functional unit is a chemical species not naturally associated with nucleic acids and wherein said functional unit imparts at least one of the following functions to the blended nucleic acid ligand: enhanced binding affinity, enhanced membrane partitioning, enhanced membrane permeability, enhanced stability, diagnostic reporting, covalent bond formation, inhibition of biological activity, said method comprising:

a) contacting the blended candidate mixture with the target, wherein blended nucleic acids having an increased affinity to the target relative to the blended candidate mixture may be partitioned from the remainder of the blended candidate mixture;

b) partitioning the increased affinity blended nucleic acids from the remainder of the blended candidate mixture; and

c) amplifying the increased affinity blended nucleic acids to yield a ligand-enriched mixture of blended nucleic acids, whereby blended nucleic acid ligands of the target compound are identified.

2. The method of claim 1 wherein said nucleic acid sequence region in the blended nucleic acid is composed of a fixed region and a randomized region.

3. The method of claim 1 wherein said functional unit is attached to an oligonucleotide hybridized to said nucleic acid sequence fixed region.

4. A blended nucleic acid ligand identified according to the method of claim 1.

5. A method for preparing blended nucleic acid ligands of a target compound comprising:

a) identifying a nucleic acid ligand of a target compound from a candidate mixture comprised of nucleic acids each having a region of randomized sequence by a method comprising: i) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and iii) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby nucleic acid ligands of the target compound are identified; and

b) attaching a functional unit, wherein said functional unit is a chemical species not naturally associated with nucleic acids, and wherein said functional unit imparts at least one of the following functions to the nucleic acid ligand: enhanced binding affinity, enhanced membrane partitioning, enhanced membrane permeability, enhanced stability, diagnostic reporting, covalent bond formation, inhibition of biological activity, to said nucleic acid ligand to yield a blended nucleic acid ligand of the target compound.

6. A blended nucleic acid ligand prepared according to the method of claim 3.

7. A blended nucleic acid ligand prepared according to the method of claim 5.

8. The method of claim 1 wherein said functional unit is a chemical species not naturally associated with nucleic acids and is selected from the group consisting of proteins, peptides, amino acids, aliphatic groups, photoreactive groups, chemically-reactive groups, active site directed compounds, catalytic groups, chloromethylketones, lipids, biotin, and fluorescent compounds.

9. The method of claim 5 wherein said functional unit is a chemical species not naturally associated with nucleic acids and is selected from the group consisting of proteins, peptides, amino acids, aliphatic groups, photoreactive groups, chemically-reactive groups, active site directed compounds, catalytic groups, chloromethylketones, lipids, biotin, and fluorescent compounds.

10. The blended nucleic acid ligand of claim 4 wherein said functional unit is a chemical species not naturally associated with nucleic acids and is selected from the group consisting of proteins, peptides, amino acids, aliphatic groups, photoreactive groups, chemically-reactive groups, active site directed compounds, catalytic groups, chloromethylketones, lipids, biotin, and fluorescent compounds.

11. The blended nucleic acid ligand of claim 7 wherein said functional unit is a chemical species not naturally associated with nucleic acids and is selected from the group consisting of proteins, peptides, amino acids, aliphatic groups, photoreactive groups, chemically-reactive groups, active site directed compounds, catalytic groups, chloromethylketones, lipids, biotin, and fluorescent compounds.

12. The method of claim 1 wherein said nucleic acid sequence region is selected from the group consisting of single-stranded DNA or single-stranded RNA.

13. The method of claim 5 wherein said nucleic acid sequence region is selected from the group consisting of single-stranded DNA or single-stranded RNA.

14. The blended nucleic acid ligand of claim 4 wherein said nucleic acid sequence region is a ribonucleotide and said functional unit is an Arg-Gly-Asp peptide, wherein said blended nucleic acid ligand binds to gpIIbIIIa.

15. The blended nucleic acid ligand of claim 4 wherein said nucleic acid sequence region is a deoxyribonucleotide and said functional unit is N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO: 2), wherein said blended nucleic acid ligand binds to elastase.

16. The blended nucleic acid ligand of claim 6 wherein said at least one functional unit is valyl phosphonate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc